Khaled Musallam: UAE Approves Pyrukynd for Both Alpha and Beta Thalassemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Some welcome and long awaited good news — and a reminder that even in challenging times, progress continues.
I am truly delighted to share that Pyrukynd (mitapivat) has now been approved in the UAE for adult patients with both alpha and beta thalassemia, including transfusion-dependent and non-transfusion-dependent forms.
This approval follows the landmark global ENERGIZE and ENERGIZE-T trials, which we were honored to participate in.
We celebrated when the trials met their primary endpoints. We celebrated when the data were presented in plenary sessions at EHA and ASH.
We celebrated again when the results were published in The Lancet.
But today marks something even more meaningful — the translation of rigorous science into real access for patients in the UAE.
Mitapivat represents the first oral disease-modifying therapy for thalassemia, addressing both anemia and transfusion burden across subtypes.
Bringing such an innovative therapy to our patients is the most important outcome we could have hoped for.
My sincere gratitude to the leadership of Burjeel Holdings for supporting what was our first global clinical trial within the group — a defining step in our research journey.
I am incredibly proud of our research and clinical teams at the Thalassemia and Sickle Cell Center and the Center for Research on Rare Blood Disorders (CR-RBD) at Burjeel Cancer Institute | BCI, BMC | Burjeel Medical City, whose dedication made this milestone possible.
This achievement would not have been possible without the exceptional support of the Department of Health Abu Dhabi.”
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care